Conformationally tailored N-(2-methy-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2- yl)carbonylproline templates as molecular tools for the design of peptidomimetics. Design and synthesis of fibrinogen receptor antagonists

Organic and Biomolecular Chemistry

Volumn 2, Issue 10, 2004, Pages 1511-1517

  Štefanič, Petra ^a   Simončič, Zvone ^a   Breznik, Matej ^a   Plavec, Janez ^b   Anderluh, Marko ^a   Addicks, Elisabeth ^c   Giannis, Athanassios ^c   Kikelj, Danijel ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BIOMIMETIC MATERIALS; CARBOXYLIC ACIDS; CHEMICAL BONDS; COMPUTER SIMULATION; CONFORMATIONS; ISOMERIZATION; SOLUTIONS; STEREOCHEMISTRY; SYNTHESIS (CHEMICAL);

AROMATIC RINGS; FIBRINOGEN RECEPTORS; INTEGRIN RECEPTORS; PROLINE BONDS;

POLYPEPTIDES;

ARGINYL GLYCYL ASPARTYL SERINE; ARGINYL-GLYCYL-ASPARTYL-SERINE; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; INTEGRIN; OLIGOPEPTIDE; PEPTIDE; PROLINE; VITRONECTIN RECEPTOR;

ARTICLE; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; CHEMOLUMINESCENCE; CONFORMATION; DRUG ANTAGONISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BINDING, COMPETITIVE; CHEMILUMINESCENT MEASUREMENTS; INTEGRINS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDES; PROLINE; RECEPTORS, FIBRINOGEN; RECEPTORS, VITRONECTIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3342955796     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b400490f     Document Type: Article

References (27)

1. J. L. Fauchère, Adv. Drug Res., 1986, 15, 29-69.
2. A. Giannis and F. Rübsam, Adv. Drug Res., 1997, 29, 1-78.
3. V. J. Hruby and P. M. Balse, Curr. Med. Chem., 2000, 7, 945-970.
4. th edn, 1995, 803-861.
5. P. Ward, J. B. Evan, C. C. Jordan, S. J. Ireland, R. M. Hagan and J. R. Brown, J. Med. Chem., 1990, 33, 1848-1851.
6. J. Zabrocki, J. B. Dunbar, Jr., K. W. Marshall, M. V. Toth and G. R. Marshall, J. Org. Chem., 1998, 63, 6572-6578.
7. J. B. M. Rewinkel and A. E. P. Adang, Curr. Pharm. Design, 1999, 5, 1043-1075.
8. M. Breznik, S. Golič Grdadolnik, G. Giester, I. Leban and D. Kikelj, J. Org. Chem., 2001, 66, 7044-7050.
9. D. Cox, T. Aoki, J. Seki, Y. Motoyama and K. Yoshida, Med. Res. Rev., 1994, 14, 195-228.
10. A. F. Horwitz, Scientific American, 1997, 68-75.
11. C. D. Eldred and B. D. Judkins, Prog. Med. Chem., 1999, 36, 29-90.
12. B. P. Eliceiri and D. A. Cheresh, Cancer J., 2000, 6(Suppl 3), 245-249.
13. R. Haubner, D. Finsinger and H. Kessler, Angew. Chem., Int. Ed. Engl., 1997, 36, 1374-1389.
14. F. M. Watt, EMBO J., 2002, 21, 3919-3926.
15. L. T. Duong, P. Lakkakorpi, I. Nakamura and G. A. Rodan, Matrix Biol., 2000, 19, 97-105.
16. L. T. Duong and G. A. Rodan, Front. Biosci., 1998, 3, 757-768.
17. D. Y. Jackson, Curr. Pharm. Design., 2002, 8, 1229-1253.
18. R. M. Scarborough and D. D. Greller, J. Med. Chem., 2000, 43, 1-21.
19. I. Ojima, S. Chakaravarty and Q. Dong, Bioorg. Med. Chem., 1995, 3, 337-360.
20. J. A. Zablocki, S. N. Rao, D. A. Baron, D. L. Flynn, N. S. Nicholson and L. P. Feigen, Curr. Pharm. Des., 1995, 1, 533-558.
21. D. Kikelj, E. Suhadolc, U. Urleb and U. Žbontar, J. Heterocycl. Chem., 1993, 30, 597-602.
22. A. W. Dow, Org. Synth., Coll. Vol. I, John Wiley & Sons Inc., New York, 2nd edn, 5-6.
23. F. A. A. M. de Leeuw and C. Altona, J. Comp. Chem., 1983, 4, 428-437.
24. E. Addicks, R. Mazitschek and A. Giannis, ChemBio Chem, 2002, 3, 1078-1088.
25. G. H. Becker, Organikum, Organisch-chemisches Grundpraktikum, Wiley-VCH, 21st edn., Weinheim, 2001.
26. F. A. A. M. de Leeuw and C. Altona, J. Comput. Chem., 1983, 4, 428-437.
27. C. Altona, R. Francke, R. de Haan, J. H. Ippel, G. J. Daalmans, A. J. A. Westra Hoekzema and J. van Wijk, Magn. Reson. Chem., 1994, 32, 670-678.